Cassava Sciences completes patient enrollment for phase 2a study for Alzheimers
Cassava Sciences announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease. Cassava Sciences is conducting this Phase 2a study with scientific and financial support from the NIH. April 15, 2019